Modulating tenascin-C functions by targeting the MAtrix REgulating MOtif, "MAREMO".

CCL21 CXCL12 Cell adhesion Chemoretention Fibronectin Gene expression Immune suppression Matrisome Matrix Regulating Motif MAREMO Matrix assembly Proteomics Signaling Structural modeling TGFβ TRAIL Tenascin-C

Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
04 2022
Historique:
received: 31 08 2021
revised: 31 01 2022
accepted: 23 02 2022
pubmed: 2 3 2022
medline: 13 4 2022
entrez: 1 3 2022
Statut: ppublish

Résumé

The extracellular matrix molecule Tenascin-C (TNC) promotes cancer and chronic inflammation by multiple mechanisms. Recently, TNC was shown to promote an immune suppressive tumor microenvironment (TME) through binding soluble chemoattracting factors, thus retaining leukocytes in the stroma. TNC also binds to fibronectin (FN) and other molecules, raising the question of a potential common TNC binding mechanism. By sequence comparison of two TNC-interacting domains in FN, the fifth (FN5) and thirteenth (FN13) fibronectin type III domains we identified a MAtrix REgulating MOtif "MAREMO" or M-motif that is highly conserved amongst vertebrates. By sequence analysis, structural modeling and functional analysis we found also putative M-motifs in TNC itself. We showed by negative staining electron microscopic imaging that the M-motif in FN mediates interactions with FN as well as with TNC. We generated two M-motif mimetic peptides P5 and P13 resembling the M-motif in FN5 and FN13, respectively. By using structural information we modelled binding of these M-motif mimetics revealing a putative MAREMO binding site MBS in FN5 and TN3, respectively overlapping with the M-motif. We further demonstrated that the M-motif mimetic peptides blocked several functions of TNC, such as binding of TNC to FN, cell rounding on a mixed FN/TNC substratum, FN matrix expression and subsequent assembly, TNC-induced signaling and gene expression, TNC chemokine binding and dendritic cell retention, thus providing novel opportunities to inhibit TNC actions. Our results suggest that targeting the MAREMO/MBS interaction could be exploited for reducing inflammation and matrix functions in cancer and fibrosis.

Identifiants

pubmed: 35227929
pii: S0945-053X(22)00025-7
doi: 10.1016/j.matbio.2022.02.007
pii:
doi:

Substances chimiques

Peptides 0
Tenascin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-38

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests The discovery of MAREMO has been protected by patent No. WO2021233766A1 on “Compounds Binding for use in the treatment of diseases”.

Auteurs

Thomas Loustau (T)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France.

Chérine Abou-Faycal (C)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France.

William Erne (W)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France.

Pia Abel Zur Wiesch (PA)

University Basel, Tumor Matrix laboratory, Department of Biomedicine, Mattenstrasse 57, Basel, Switzerland.

Ayoub Ksouri (A)

Laboratoire des Venins et Molécules Thérapeutiques, Institut Pasteur Tunis, 13 Place Pasteur, BP74, 1002, Tunis, Tunisia; Medical School of Tunis, Tunis Université, Tunis, Tunisia.

Thomas Imhof (T)

Institute for Dental Research and Oral Musculoskeletal Research, Center for Biochemistry, Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Joseph-Stelzmann-Str. 52, Cologne, Germany.

Matthias Mörgelin (M)

Colzyx AB, Scheelevägen 2, 223 81 Lund, Sweden.

Chengbei Li (C)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France.

Malaurie Mathieu (M)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France.

Nathalie Salomé (N)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France.

Gerard Crémel (G)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France.

Sayda Dhaouadi (S)

Laboratoire des Venins et Molécules Thérapeutiques, Institut Pasteur Tunis, 13 Place Pasteur, BP74, 1002, Tunis, Tunisia; Medical School of Tunis, Tunis Université, Tunis, Tunisia.

Balkiss Bouhaouala-Zahar (B)

Laboratoire des Venins et Molécules Thérapeutiques, Institut Pasteur Tunis, 13 Place Pasteur, BP74, 1002, Tunis, Tunisia; Medical School of Tunis, Tunis Université, Tunis, Tunisia.

Manuel Koch (M)

Institute for Dental Research and Oral Musculoskeletal Research, Center for Biochemistry, Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Joseph-Stelzmann-Str. 52, Cologne, Germany.

Gertraud Orend (G)

University Strasbourg, INSERM U1109, MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy), 3 avenue Molière, Strasbourg, Hautepierre, France; University Strasbourg, INSERM U1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 1 Place de l'Hôpital, 67091 Strasbourg, France; University Basel, Tumor Matrix laboratory, Department of Biomedicine, Mattenstrasse 57, Basel, Switzerland. Electronic address: gertraud.orend@inserm.fr.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
C-Reactive Protein Humans Biomarkers Inflammation
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

Classifications MeSH